These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38476752)

  • 41. RSV Prevention in All Infants: Which Is the Most Preferable Strategy?
    Esposito S; Abu Raya B; Baraldi E; Flanagan K; Martinon Torres F; Tsolia M; Zielen S
    Front Immunol; 2022; 13():880368. PubMed ID: 35572550
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Potential impact of nirsevimab and bivalent maternal vaccine against RSV bronchiolitis in infants: A population-based modelling study.
    López-Lacort M; Corberán-Vallet A; Santonja FJ; Muñoz-Quiles C; Díez-Domingo J; Orrico-Sánchez A
    J Infect Public Health; 2024 Aug; 17(8):102492. PubMed ID: 39002465
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The contribution of child, family and health service factors to respiratory syncytial virus (RSV) hospital admissions in the first 3 years of life: birth cohort study in Scotland, 2009 to 2015.
    Hardelid P; Verfuerden M; McMenamin J; Smyth RL; Gilbert R
    Euro Surveill; 2019 Jan; 24(1):. PubMed ID: 30621817
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
    Régnier SA
    Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nirsevimab: Alleviating the burden of RSV morbidity in young children.
    Loe MWC; Soenong H; Lee E; Li-Kim-Moy J; Williams PC; Yeo KT
    J Paediatr Child Health; 2024 Oct; 60(10):489-498. PubMed ID: 39150043
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Maternal vaccination against RSV can substantially reduce childhood mortality in low-income and middle-income countries: A mathematical modeling study.
    Willemsen JE; Borghans JAM; Bont LJ; Drylewicz J
    Vaccine X; 2023 Dec; 15():100379. PubMed ID: 37711264
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost of childhood RSV management and cost-effectiveness of RSV interventions: a systematic review from a low- and middle-income country perspective.
    Wittenauer R; Pecenka C; Baral R
    BMC Med; 2023 Mar; 21(1):121. PubMed ID: 37004038
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Respiratory Syncytial Virus (RSV) Burden in Infants in the Kingdom of Saudi Arabia and the Impact of All-Infant RSV Protection: A Modeling Study.
    Alharbi A; Yousef A; Zubani A; Alzahrani M; Al-Hindi M; Alharbi S; Alahmadi T; Alabdulkarim H; Kazmierska P; Beuvelet M
    Adv Ther; 2024 Apr; 41(4):1419-1435. PubMed ID: 38356106
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluating the impact of a continued maternal pertussis immunisation programme in England: A modelling study and cost-effectiveness analysis.
    Sandmann F; Jit M; Andrews N; Buckley HL; Campbell H; Ribeiro S; Sile B; Stowe J; Tessier E; Ramsay M; Amirthalingam G; Choi YH
    Vaccine; 2021 Jul; 39(32):4500-4509. PubMed ID: 34183204
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
    Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
    Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New respiratory syncytial virus immunization products in low- and middle-income countries: potential for cost-effective impact on a high burden of disease in young infants.
    Srikantiah P; Klugman KP
    BMC Med; 2023 May; 21(1):177. PubMed ID: 37183242
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Value profile for respiratory syncytial virus vaccines and monoclonal antibodies.
    Fleming JA; Baral R; Higgins D; Khan S; Kochar S; Li Y; Ortiz JR; Cherian T; Feikin D; Jit M; Karron RA; Limaye RJ; Marshall C; Munywoki PK; Nair H; Newhouse LC; Nyawanda BO; Pecenka C; Regan K; Srikantiah P; Wittenauer R; Zar HJ; Sparrow E
    Vaccine; 2023 Nov; 41 Suppl 2():S7-S40. PubMed ID: 37422378
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Burden of hospital admissions caused by respiratory syncytial virus (RSV) in infants in England: A data linkage modelling study.
    Reeves RM; Hardelid P; Panagiotopoulos N; Minaji M; Warburton F; Pebody R
    J Infect; 2019 Jun; 78(6):468-475. PubMed ID: 30817978
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study.
    Shoukat A; Bawden CE; Röst G; LeBlanc JJ; Galvani AP; Langley JM; Moghadas SM
    Vaccine; 2024 Mar; 42(7):1768-1776. PubMed ID: 38368226
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness and programmatic benefits of maternal vaccination against pertussis in England.
    van Hoek AJ; Campbell H; Amirthalingam G; Andrews N; Miller E
    J Infect; 2016 Jul; 73(1):28-37. PubMed ID: 27108802
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
    Joffe S; Ray GT; Escobar GJ; Black SB; Lieu TA
    Pediatrics; 1999 Sep; 104(3 Pt 1):419-27. PubMed ID: 10469764
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Exploring parental perspectives: Maternal RSV vaccination versus infant RSV monoclonal antibody.
    Treston B; Geoghegan S
    Hum Vaccin Immunother; 2024 Dec; 20(1):2341505. PubMed ID: 38723786
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study.
    Christensen H; Trotter CL; Hickman M; Edmunds WJ
    BMJ; 2014 Oct; 349():g5725. PubMed ID: 25301037
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mitigation of respiratory syncytial virus epidemics by RSVpreF vaccines after the COVID-19 pandemic in the UK: a modelling study.
    Du Z; Wang L; Bai Y; Pei Y; Wu P; Cowling BJ
    Lancet; 2023 Nov; 402 Suppl 1():S39. PubMed ID: 37997080
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA; Cosgrove JF; MacMahon P
    Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.